Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 22 August are set out below…
Pearce IP’s CEO, Naomi Pearce, discusses changes in New Zealand High Court procedure with our Head of Litigation (NZ), Paul Johns. As those changes are based on similar reforms made earlier in Australia, light is shed on their potential effects by the Head of Litigation (Australia), Helen Macpherson.
No interlocutory injunction (‘preliminary injunction’ or ‘PI’) has been granted in any pharmaceutical patent dispute since 2018. The Federal Court’s refusal last week of Regeneron and Bayer’s PI
Pearce IP is Australasian Lawyer and NZ Lawyer’s 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees)
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 29 August are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 22 August are set out below…
In a unanimous decision, Justices Burley, Rofe and Downes of the Full Court of the Federal Court have dismissed Novartis’ appeal against the first instance decision of Justice Yates who found that Pharmacor’s…
Naomi Pearce Ranked Among the World’s Leading IP Strategists in IAM Strategy 300
In a unanimous decision, Justices Burley, Rofe and Downes of the Full Court of the Federal Court have dismissed Novartis’ appeal against the first instance decision of Justice Yates who found that Pharmacor’s…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 8 August are set out below…
Pearce IP’s Head of Litigation (NZ), Paul Johns, and Head of Trade Marks, Kimberley Evans, discuss the third party “revival” of the ANSETT brand in 2025 for travel agency services, more than 20 years after the airline folded.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 1 August are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 25 July are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 18 July are set out below…
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
In this PiPCast™, Pearce IP’s Head of Trade Marks, Kimberley Evans, speaks to CEO, Naomi Pearce, about current trade mark examination trends in Australia and New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 July are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 4 July are set out below…
On 5 February 2025, Justice Downes of the Federal Court of Australia delivered her decision in the dispute between Otsuka Japan and its licensees (Lundbeck A/S and Australia and Otsuka Australia) (collectively…
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 June are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 June are set out below…
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
